Perspective Therapeutics Inc [CATX] stock is trading at $12.19, up 0.83%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CATX shares have gain 2.35% over the last week, with a monthly amount drifted -8.69%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Perspective Therapeutics Inc [AMEX: CATX] stock has seen the most recent analyst activity on October 24, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $20. Previously, Wedbush started tracking the stock with Outperform rating on October 01, 2024, and set its price target to $25. On September 25, 2024, Truist initiated with a Buy rating and assigned a price target of $21 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $24 on July 25, 2024. Cantor Fitzgerald initiated its recommendation with a Overweight.
Perspective Therapeutics Inc [CATX] stock has fluctuated between $2.20 and $19.05 over the past year. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Perspective Therapeutics Inc [AMEX: CATX] shares were valued at $12.19 at the most recent close of the market. An investor can expect a potential return of 47.66% based on the average CATX price forecast.
Analyzing the CATX fundamentals
Perspective Therapeutics Inc [AMEX:CATX] reported sales of 8.84M for the trailing twelve months, which represents a drop of -74.50%. Gross Profit Margin for this corporation currently stands at 0.04% with Operating Profit Margin at -6.43%, Pretax Profit Margin comes in at -6.21%, and Net Profit Margin reading is -6.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.21 and Total Capital is -0.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.69 points at the first support level, and at 11.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.80, and for the 2nd resistance point, it is at 13.40.
Ratios To Look Out For
For context, Perspective Therapeutics Inc’s Current Ratio is 27.73. Further, the Quick Ratio stands at 27.73, while the Cash Ratio is 2.22. Considering the valuation of this stock, the price to sales ratio is 95.18, the price to book ratio is 2.41.
Transactions by insiders
Recent insider trading involved Mark Austin, affiliate, that happened on Sep 12 ’24 when 2500.0 shares were purchased. Chief Financial Officer, Hunt Jonathan Robert completed a deal on Jun 17 ’24 to buy 1800.0 shares. Meanwhile, Director Woods Lori A bought 4587.0 shares on Jun 14 ’24.
